Inactive Instrument

Zogenix, Inc.

ZGNX

US98978L2043

Zogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

February 28, 2022 at 08:09 am EST

Zogenix, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was USD 81.69 million compared to USD 13.64 million a year ago. Net loss was USD 227.41 million compared to USD 209.38 million a year ago.

Basic loss per share from continuing operations was USD 4.07 compared to USD 3.9 a year ago.

Latest news about Zogenix, Inc.

Pulmocide Announces Expansion of Management Team	23-06-08	CI
U.S. FDA approves UCB's drug for rare childhood epilepsy	22-03-28	RE
Zogenix Completes $1.9 Billion Buyout by UCB; Shares Delisted From Nasdaq	22-03-07	MT
UCB Closes Zogenix Acquisition for Nearly $1.9 Billion	22-03-07	MT
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from NASDAQ Composite Index	22-03-07	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from S&P Pharmaceuticals Select Industry Index	22-03-07	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from S&P TMI Index	22-03-07	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from S&P Global BMI Index	22-03-07	CI
UCB BioSciences, Inc. completed the acquisition of Zogenix, Inc..	22-03-03	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from NASDAQ Biotechnology Index	22-03-01	CI
Northland Downgrades Zogenix to Market Perform From Outperform, Lifts Price Target to $27 From $26	22-02-28	MT
Zogenix Q4 Loss Narrows, Revenue Increases	22-02-28	MT
Zogenix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-28	CI
Zogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-28	CI
Earnings Flash (ZGNX) ZOGENIX Posts Q4 Revenue $26.6M	22-02-28	MT
Health Care Stocks Floundering Late in Wednesday Trading	22-01-19	MT
JMP Securities Downgrades Zogenix to Market Perform From Market Outperform	22-01-19	MT
Top Midday Gainers	22-01-19	MT
Health Care Stocks Moderately Higher Wednesday Afternoon	22-01-19	MT
Needham & Co Downgrades Zogenix to Hold From Buy	22-01-19	MT
Guggenheim Downgrades Zogenix to Neutral From Buy, Adjusts Price Target to $28 From $35	22-01-19	MT
William Blair Downgrades Zogenix to Market Perform From Outperform	22-01-19	MT
Zogenix Agrees to $1.9 Billion Takeover by UCB; Shares Surge	22-01-19	MT
Wall Street Set for Recovery After Bond Yield-Induced Sell-Off	22-01-19	MT
Health Care Stocks Edge Higher Premarket Wednesday	22-01-19	MT

Chart Zogenix, Inc.

Duration

Period

More charts

Company Profile

Zogenix Inc is a United States-based biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for rare diseases. It is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. The Company also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-4.06%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+55.96%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals